Ravidasvir
- Generic Name
- Ravidasvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H50N8O6
- CAS Number
- 1242087-93-9
- Unique Ingredient Identifier
- AL3G001BI8
- Background
Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).
- Indication
联合利托那韦强化的达诺瑞韦钠片和利巴韦林，用于治疗初治的基因1b型慢性丙型肝炎病毒感染的非肝硬化成人患者，不得作为单药治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 584
- Registration Number
- NCT04501952
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸NorthStar Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Baltimore, Baltimore, Maryland, United States
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 425
- Registration Number
- NCT03362814
- Locations
- 🇨🇳
Peking University People's hospital, Beijing, Beijing, China
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03288636
- Locations
- 🇨🇳
The first hospital of Zhejiang province, Hangzhou, Zhejiang, China
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03020134
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath